SIO GENE THERAPIES INC (SIOX)

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

–  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022...

Sio Gene Therapies to dissolve company, liquidate assets (NASDAQ:SIOX)

The board of microcap Sio Gene Therapies (SIOX) has decided to dissolve the company and liquidate its assets following a review of potential strategic alternatives.

Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after...

Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022...

Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday!

Sio Gene Therapies Provides Corporate Update

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB...